3M Company (3M CO) - Q1 2004 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended March 31, 2004. 3M is a diversified global manufacturer and technology innovator operating in seven segments: Health Care, Industrial, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, Electro and Communications, and Transportation. The company reported 782.1 million shares of common stock outstanding as of the period end.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $4,939 | $4,318 |
| Operating Income | $1,117 | $781 |
| Net Income | $722 | $502 |
| Diluted EPS | $0.90 | $0.63 |
| Operating Cash Flow | $942 | $764 |
| Cash and Equivalents | $1,818 | $561 |
| Total Debt | $2,824 | $2,937 |
| Net Debt | $1,006 | $1,101 |
| Operating Margin | 22.6% | 18.1% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14.4% year-over-year, driven by core volume growth of 8.4% and favorable currency translation (6.1%). All seven business segments reported sales growth.
- Profitability: Operating income surged 43.1% to $1.117 billion. This improvement was significantly aided by the absence of a $93 million pre-tax charge recorded in Q1 2003 related to the LePage's Inc. lawsuit.
- Cost Management: Cost of sales as a percentage of net sales decreased 1.9 percentage points to 49.3%, attributed to higher volumes, productivity gains, and favorable mix.
- Acquisitions: The company acquired HighJump Software, Inc. (supply chain software) and a 91% stake in Hornell Holding AB (welding safety equipment) for a combined purchase price of approximately $161 million.
- Currency Impact: Foreign currency effects positively impacted net income by an estimated $57 million and operating income by $90 million.
Guidance, Outlook, and Risks
- Outlook: Management expects Health Care sales growth to accelerate in late 2004, aided by the immune response modifier (IRM) platform. The company anticipates regulatory approval for Aldara (imiquimod) Cream for superficial basal cell carcinoma in the second half of 2004.
- Capital Allocation: The Board increased the quarterly dividend by 9.1% to $0.36 per share. The company repurchased $438 million of common stock in the quarter, with $1.092 billion remaining under the current authorization.
- Legal Contingencies:
- Breast Implants: An arbitration panel rejected claims for coverage under certain policies, leading to a $16 million reduction in insurance receivables.
- Asbestos/Respirator Masks: The company faces approximately 89,800 individual claims, with accrued liabilities of $267 million and receivables of $448 million.
- Antitrust: A federal court rejected a motion for class certification in a LePage's-related antitrust case, though the plaintiff has filed for reconsideration.
- Risks: Key risks include foreign currency fluctuations (over 50% of revenue is international), raw material cost volatility, and the timing of new product regulatory approvals.
Investor Verification Checklist
- Legal Exposure: Verify the status of the breast implant arbitration ruling and the potential impact on future insurance recoveries.
- Pharmaceutical Pipeline: Monitor the FDA review timeline for Aldara's approval for superficial basal cell carcinoma, which is critical for the Health Care segment's late-year growth.
- Asbestos Litigation: Track developments in Congressional legislation regarding asbestos reform, which could materially alter liability estimates.
- Currency Sensitivity: Assess the impact of a strengthening U.S. dollar on future earnings, given the company's heavy international revenue exposure.
- Acquisition Integration: Review the performance of the newly acquired HighJump Software and Hornell Holding AB in subsequent quarters.